No abstract

Background. Magnesium sulfate reduces pain scores and analgesic consumption. Its use as an analgesic resource in opioid-free or opioid-sparing techniques have also been tested. The evaluation of the antinociceptive potency of drugs and doses indirectly, through hemodynamic oscillations has been questioned. A relatively new algorithm called the plethysmographic stress index has been considered sensitive and relatively specific as a parameter for assessing the need for intraoperative analgesia. Objectives. The aim of this trial was to assess the intraoperative analgesic capacity of magnesium sulfate compared to remifentanil. The secondary objectives were propofol consumption and its latency, the consumption of opioids, ephedrine, and cisatracurium. Patients and Methods. Forty patients scheduled for post-bariatric dermolipectomy were randomly assigned to two groups to receive total intravenous anesthesia with target-controlled hypnosis induced with propofol. Analgesia was obtained in the remifentanil group with remifentanil at an initial dose of 0.2 μg·kg−1·min−1 and in the magnesium sulfate group with magnesium sulfate 40 mg·kg−1 + 10 mg·kg−1·h−1. Results. There was no statistical hemodynamic difference between the groups before and after orotracheal intubation ( p  = 0.062) and before and after the surgical incision ( p  = 0.656). There was also no statistical difference in the variation of mean arterial pressure before and after intubation ( p  = 0.656) and before and after the surgical incision ( p  = 0.911). There was similar consumption of cisatracurium, ephedrine, and postoperative opioids between the groups. Some patients in the magnesium sulfate group needed more intraoperative fentanyl and propofol, although the latency of propofol was similar in both the groups. Conclusion. We conclude that using magnesium sulfate in intravenous general anesthesia for post-bariatric dermolipectomy is related to a significant reduction in opioid consumption without compromising hemodynamic stability. Overall, PSI monitoring was helpful in driving the analgesic strategy. The use of magnesium sulfate proved to be an important adjunct in the scenario presented, allowing the use of opioids to be avoided in certain cases. We found no statistical differences in the consumption of neuromuscular blocker and vasoconstrictor. Substituting opioids for magnesium sulfate leads to an increase in propofol consumption in the scenario presented. Studies with a larger sample are needed to corroborate the results presented and evaluate other potential advantages in reducing opioid consumption.

Background. Magnesium sulfate has analgesic properties during the postoperative period. However, there is a knowledge gap in pharmacology related to the use of the real, ideal, or corrected ideal body weight to calculate its dose in obese patients. This trial compared postoperative analgesia using actual and corrected ideal body weight. Methods. Seventy-five obese patients scheduled to undergo laparoscopic gastroplasty or cholecystectomy under general anesthesia were randomly assigned to three groups. The patients in the control group did not receive magnesium sulfate; the other two groups received magnesium sulfate at 40 mg·kg−1 of actual body weight or corrected ideal body weight. Results. In patients with body mass index >30 mg·kg−2 (mean body mass index ranging from 32.964 kg·m−2 to 33.985 kg·m−2, according to the groups) scheduled for video laparoscopic cholecystectomy, there were no differences in the blood magnesium concentrations in the groups receiving magnesium sulfate throughout the study, regardless of whether the strategy to calculate its dose was based on total or corrected ideal body weight. Patients in the groups receiving magnesium sulfate showed a significant reduction in morphine consumption ( p ≤ 0.001 ) and pain scores ( p = 0.006 ) in the postoperative period compared to those in the control group. There were no significant differences in morphine consumption ( p = 0.323 ) or pain scores ( p = 0.082 ) between the two groups receiving magnesium sulfate. There were no differences in the total duration of neuromuscular block induced by cisatracurium among the three groups ( p = 0.181 ). Conclusions. Magnesium sulfate decreased postoperative pain and morphine consumption without affecting the recovery time of cisatracurium in obese patients undergoing laparoscopic cholecystectomy. Strategies to calculate the dose based on the actual or corrected ideal body weight had similar outcomes related to analgesia and the resulting blood magnesium concentration. However, as the sample in this trial presented body mass indices ranging from 30.11 kg·m−2 to 47.11 kg/m−2, further studies are needed to confirm these findings in more obese patients, easily found in centers specialized.

BACKGROUNDMagnesium sulfate has analgesic properties in the postoperative period. Among obese patients, there is a gap in the knowledge of its pharmacology related to the use of real, ideal, or corrected ideal body weight in calculating its dose. This trial compared postoperative analgesia using actual and corrected ideal body weight.METHODSSeventy-five obese patients scheduled to undergo laparoscopic cholecystectomy under general anesthesia were randomly assigned to three groups. Patients in the control group received no magnesium sulfate; patients in the other two groups received magnesium sulfate 40 mg·kg− 1 of actual body weight or corrected ideal body weight. A ten nonobese patients group helped us as a model of the expected blood magnesium concentration after magnesium sulfate administration in general population.RESULTSPatients from the groups receiving magnesium sulfate showed significant reduction in morphine consumption (p ≤ 0.001) and pain scores (p = 0.006) in the postoperative period compared to the control group. There was no significant difference in the consumption of morphine (p = 0.323) or pain scores (p = 0.082) between these groups. There was no difference in the total duration of neuromuscular block induced by cisatracurium among the three groups (p = 0.181) or in the blood magnesium concentrations throughout the study.CONCLUSIONSMagnesium sulfate decreased postoperative pain and morphine consumption without affecting cisatracurium recovery time in obese patients undergoing laparoscopic cholecystectomy. Analgesic profile was similar in groups receiving magnesium sulfate calculated through real or corrected ideal body weight.TRIAL REGISTRATIONclinicaltrials.gov NCT04003688. (Date of registration: June 24, 2019)